{
    "clinical_study": {
        "@rank": "159997", 
        "brief_summary": {
            "textblock": "RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction\n      that cannot be removed by surgery to live longer and more comfortably.\n\n      PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in\n      treating patients who have cancer-related bowel obstruction that cannot be removed by\n      surgery."
        }, 
        "brief_title": "Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery", 
        "completion_date": {
            "#text": "October 2002", 
            "@type": "Actual"
        }, 
        "condition": [
            "Colorectal Cancer", 
            "Constipation, Impaction, and Bowel Obstruction", 
            "Extrahepatic Bile Duct Cancer", 
            "Gastric Cancer", 
            "Gastrointestinal Stromal Tumor", 
            "Nausea and Vomiting", 
            "Ovarian Cancer", 
            "Pancreatic Cancer", 
            "Peritoneal Cavity Cancer", 
            "Small Intestine Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Constipation", 
                "Fecal Impaction", 
                "Intestinal Obstruction", 
                "Stomach Neoplasms", 
                "Nausea", 
                "Vomiting", 
                "Ovarian Neoplasms", 
                "Pancreatic Neoplasms", 
                "Duodenal Neoplasms", 
                "Ileal Neoplasms", 
                "Jejunal Neoplasms", 
                "Bile Duct Neoplasms", 
                "Peritoneal Neoplasms", 
                "Gastrointestinal Stromal Tumors", 
                "Intestinal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the effectiveness of octreotide in the palliation of bowel obstruction\n           secondary to cancer.\n\n        -  Characterize the dose and tolerability of octreotide in this patient population.\n\n      OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5.\n\n      Patients who respond well to study may continue octreotide for palliative effects.\n\n      PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Inoperable bowel obstruction secondary to cancer OR\n\n          -  Metastatic or primary abdominal cancer\n\n          -  Patient presents with vomiting\n\n          -  Percutaneous gastrostomy tube allowed\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Over 18\n\n        Performance status:\n\n          -  ECOG 0-4\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Not specified\n\n        Other:\n\n          -  No documented hypersensitivity to octreotide\n\n          -  Not pregnant or nursing\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  Prior chemotherapy allowed\n\n        Endocrine therapy:\n\n          -  Concurrent steroids allowed\n\n        Radiotherapy:\n\n          -  Prior radiotherapy allowed\n\n        Surgery:\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "March 7, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004895", 
            "org_study_id": "NU 97X1", 
            "secondary_id": [
                "NU-97X1", 
                "NCI-G00-1685"
            ]
        }, 
        "intervention": {
            "intervention_name": "octreotide acetate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Octreotide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage I colon cancer", 
            "stage II colon cancer", 
            "stage III colon cancer", 
            "stage IV colon cancer", 
            "stage I gastric cancer", 
            "stage II gastric cancer", 
            "stage III gastric cancer", 
            "stage IV gastric cancer", 
            "recurrent gastric cancer", 
            "stage I pancreatic cancer", 
            "stage II pancreatic cancer", 
            "stage III pancreatic cancer", 
            "stage IV pancreatic cancer", 
            "recurrent pancreatic cancer", 
            "stage I rectal cancer", 
            "stage II rectal cancer", 
            "stage III rectal cancer", 
            "stage IV rectal cancer", 
            "recurrent colon cancer", 
            "recurrent rectal cancer", 
            "stage I ovarian epithelial cancer", 
            "stage II ovarian epithelial cancer", 
            "stage III ovarian epithelial cancer", 
            "stage IV ovarian epithelial cancer", 
            "recurrent ovarian epithelial cancer", 
            "small intestine adenocarcinoma", 
            "small intestine lymphoma", 
            "small intestine leiomyosarcoma", 
            "localized extrahepatic bile duct cancer", 
            "unresectable extrahepatic bile duct cancer", 
            "recurrent extrahepatic bile duct cancer", 
            "recurrent small intestine cancer", 
            "constipation, impaction, and bowel obstruction", 
            "peritoneal cavity cancer", 
            "nausea and vomiting", 
            "gastrointestinal stromal tumor"
        ], 
        "lastchanged_date": "May 31, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60611-3013"
                }, 
                "name": "Robert H. Lurie Comprehensive Cancer Center, Northwestern University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study", 
        "overall_official": {
            "affiliation": "Robert H. Lurie Cancer Center", 
            "last_name": "J. Cameron Muir, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2002", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004895"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Northwestern University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Northwestern University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 1999", 
        "study_design": "Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }, 
    "geocoordinates": {
        "Robert H. Lurie Comprehensive Cancer Center, Northwestern University": "41.878 -87.63"
    }
}